Clinical Trials Browser

Interleukin-2 × Other solid neoplasm × Clear all

NCT06598371 2026-04-16

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Select Advanced Solid Tumors

NCT07443020 2026-04-07

RIOT 4B

Phase 1 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant, Pleural Effusion, Malignant

NCT07192900 2026-01-15

(RIOT 4A)

Phase 1 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant, Pleural Effusion, Malignant

NCT05307874 2025-12-24

EVICTION-2

Phase 1/2 Completed

Other solid neoplasm

Solid Tumor, Adult

NCT05881525 2025-07-16

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT05086692 2025-07-09

ABILITY-1

Phase 1/2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04643574 2025-02-14

NeoTIL in Advanced Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor, Adult

NCT03546426 2024-10-01

MESOVAX

Phase 1 Active not recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant, Disease Progression

NCT03891706 2024-09-19

Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Solid Tumor

NCT02414945 2023-01-10

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

Phase 1/2 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05649618 2022-12-14

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

Phase EARLY_PHASE1 Unknown

Other solid neoplasm

Solid Tumor

NCT05648994 2022-12-13

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Phase EARLY_PHASE1 Unknown

Other solid neoplasm

Solid Tumors

NCT04892498 2022-08-09

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Phase 2 Unknown

Other solid neoplasm

Advanced Refractory Solid Tumors

NCT03992326 2021-03-18

Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumor, Adult

NCT02070406 2019-02-28

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Phase 1 Terminated

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT03171220 2017-06-06

NRT-01

Phase 1/2 Unknown

Other solid neoplasm

Advanced Malignant Solid Tumor

NCT00002994 2016-06-28

Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors

Phase 1 Completed

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00005604 2013-02-01

Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific